Spark Therapeutics enters into definitive merger agreement with Roche

Spark Therapeutics Announces Pricing and First-of-their-kind Patient Access Programs

FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl)